Overview

Safety and Efficacy of Bivalirudin Versus Heparin for Systemic Anticoagulation in Extracorporeal Membrane Oxygenation

Status:
Unknown status

Trial end date:
2020-12-31

Target enrollment:

Participant gender:

Summary

This study will evaluate heparin as compared to bivalirudin for systemic anticoagulation in adult patients that require extracorporeal membrane oxygenation (ECMO). Half of the participants will receive heparin and half will receive bivalirudin.

Phase:

Phase 4

Details

Lead Sponsor:

Legacy Health System

Collaborator:

Pacific University

Treatments:

Bivalirudin
Calcium heparin
Heparin
Hirudins